Margin trendWarning
영업이익률 악화 (19.7% → 10.9%, -8.7%p). 통계적 정황 신호이며 회계부정 단정이 아닙니다.
J2KBIO
A420570 · KOSDAQ₩9,450+2.38%
2026-08-03 closeJ2KBIO — what's the grade? And what signals are flashing today?
Open the exact grade & valuation bands with Pro →Loading chart…
CloseMA20MA60MA120
AI Insight
Why these signals fired — only backtest-proven edge, told honestly
Why this signalSignal guide
Moving-average alignment
Yes · score 0.58
Strong-buy signal — the real recordrecord · not a prediction
Not this one stock, but every strong-buy pick we actually published (Korea market). When this stock flashes the signal, it is treated by the same rule.(as of 2026-08-03)
Last 30 sessions
648 picks
Next-day win rate
49.2%
Avg next-day
-0.17%
vs market
+0.72%p
Beat the market on 62.1% of picks (each pick vs its own day’s market average).
Recent publish days (next-day win rate)
07-31 0%07-30 66.7%07-29 0%07-28 45%07-27 20%07-25 36.4%07-21 55.6%07-20 53.8%07-16 53.3%07-15 50%07-14 71.4%07-13 31.2%
This stock has not flashed this signal recently — the record above is the signal’s own, not this stock’s.
Entry is the latest close at publish time; next-day is the following close. “Market” is the equal-weighted average of every stock in the same market that day; delisted names are excluded from both. Fees, taxes and slippage are not included. An observed record over a short window, not a pre-registered backtest. Not investment advice.
Valuation Grades
Relative to 110 화학 peers · not investment advice
Annual dividend
Split-adjusted annual DPS history and available grade axes
Paid 1 consecutive years · Raised 0 consecutive years · Yield 2.12% (based on 2025 payment of 200원)
Per-share amount adjusted for splits and capital reductions · Factual information, not investment advice.
Financial safety
Reference indicatorAs of 2024Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 12.16
Distress
Grey
Safe
- Altman Z''
- 12.16
- Beneish M-Score
- -3.75
- Sloan accrual
- -23.88%
No statistical flag
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
5/9Moderate
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score5/9
Profitability
- Positive ROANot passed
- Positive OCFPass
- Improving ΔROANot passed
- Accruals (OCF > net income)Pass
Leverage & liquidity
- Lower debtPass
- Higher current ratioPass
- No new sharesPass
Efficiency
- Higher gross marginNot passed
- Higher asset turnoverNot passed
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Forensic signals
Anomaly and structural signals observed in the financial statements.
Margin trendWarning
영업외손익 급변 (영업이익 대비 125% 규모 변동) — 일회성 손익 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Factual information, not investment advice.
Industry structure
KRAs of 2026-08-03화학
This stock is in 화학: revenue rank 100 of 109, share 0%.
100 / 1090%revenue share
Who dominates this industry?
- 1LG화학31.9%
- 2롯데케미칼13.3%
- 3금호석유화학4.7%
- 4DL3.7%
- 5코오롱인더3.2%
- 6제이투케이바이오0%
Concentration
DistributedCR3 49.9%HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.
Polarization
MixedConsistentPolarization measures industry gaps and structure, not valuation, forecast, or investment advice.
Margin lens
- IQR%p
- 8.66
- Direction
- 확대
- Level
- 보통
- Years
- 6
Value lens
- P90/P10
- 9.3
- Median P/B
- 0.71
- Level
- 넓음
- n
- 98
Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Base metrics
- Operating margin
- 10.9%
- Interest coverage
- 37.9x
- Return on equity (ROE)
- -5.3%
Operating margin −5pp
TolerableInterest coverageBase 37.9x adverse case 20.6x
Return on equity (ROE)Base -5.3% adverse case 6%
Revenue −15%
TolerableInterest coverageBase 37.9x adverse case 32.2x
Return on equity (ROE)Base -5.3% adverse case 9.5%
Interest rate +2pp
TolerableInterest coverageBase 37.9x adverse case 19.3x
Return on equity (ROE)Base -5.3% adverse case 11%
Interest coverage limit
Current margin 10.7ppInterest coverage limit at an operating margin of 0.3%
Interest expense coverage threshold
Key suppliers · Annual report
Annual reportDART · 2026-03-19Suppliers disclosed by the company in its 2026-03-19 annual report.
Suppliers without disclosed amount
Financials at a glance
J2KBIO's latest results and balance sheet. The bars track the last three periods.
Who held it · filings
Filed recordA historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.
US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.
5%+ major-holding disclosures
- 이재섭63.27%2024-10-31 · 증감 -2.14%p
Connections
AI-extracted related companies · for reference
Customers
Competitors
Same theme
Recent filings
J2KBIO's latest filings on Korea's DART. Open a headline for a reference summary and the original.
Source: DART (Korea electronic disclosure)
Signal history (last ~2 years)
Every occurrence on this stock, with the return 20 trading days later. Small sample — a record, not a prediction.
New MA alignment×2
26-08-03·26-07-28·
“·” = fewer than 20 trading days since the event. Cup-and-handle entries are days our board actually showed the badge (archive grows daily since 2026-05-12); others are recomputed from price data.
Like these rules? Run them automatically.
Quantus turns rules like these into backtests and automated trading — same team, free to start.
Quantus Signal · live data · not investment advice · Privacy Policy